Mentioned In Despatches: Ablynx's Story From The Frontline Of The Biotech Boom
A little over 12 months ago, Belgian Nanobody biotech Ablynx was at the center of a bidding war between Novo Nordisk and Sanofi. Ex-Ablynx CEO Edwin Moses talked to Scrip about the four-month period that changed the course of the company.
You may also be interested in...
Having signed a major alliance expansion with Gilead, Onno van Stolpe tells Scrip that any takeover talk about Galapagos would be "unacceptable and unwanted."
Cablivi is first therapeutic to receive positive CHMP opinion for treating acquired thrombotic thrombocytopenic purpura, a rare blood disorder.
Success in the clinic with caplacizumab for aTTP and a big IPO in the USA has put the Belgium-headquartered group in the spotlight.